Xerostomia Therapeutics Market Report 2025

The xerostomia therapeutics market size has grown steadily in recent years. It will grow from $2.14 billion in 2024 to $2.24 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to increasing incidences of xerostomia in the geriatric population, research and development of efficient products for xerostomia, growing awareness about xerostomia-related products, increasing of medical conditions, and rising prevalence of chronic diseases.

The xerostomia therapeutics market size is expected to see steady growth in the next few years. It will grow to $2.69 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to easy availability of cost-effective medications in the market, increased prevalence of oral health conditions, rising awareness among healthcare practitioners, government initiatives, and increased medication use. Major trends in the forecast period include artificial saliva and saliva substitutes, technological advancements and product innovations, personalized medicine and targeted therapies, telehealth and remote monitoring, and rise of non-invasive therapies.

The forecast of 4.7% growth over the next five years reflects a modest reduction of 0.7% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oral medicine specialists by inflating prices of pilocarpine hydrochloride and cevimeline active pharmaceutical ingredients sourced from India and Israel, resulting in delayed dry mouth symptom relief and higher salivary gland therapy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing utilization of chemotherapy in cancer care is anticipated to drive the expansion of the xerostomia therapeutics market in the future. Chemotherapy, a cornerstone of cancer treatment, employs potent medications to target and suppress the proliferation of cancer cells, contributing significantly to improved patient outcomes. Xerostomia therapeutics encompass various interventions such as saliva-stimulating medications and mouth rinses designed to alleviate dry mouth symptoms, enhance saliva production, and improve taste sensation, thereby facilitating proper nutrition and oral comfort for patients undergoing cancer treatment. For example, as of January 2022, the National Cancer Institute reported an estimated 18.1 million cancer survivors in the United States, constituting 5.4% of the total population. By 2032, this number is projected to reach 22.5 million worldwide, reflecting a 24.4% increase from current estimates. Hence, the rising adoption of chemotherapy in cancer management is a key driver behind the growth of the xerostomia therapeutics market.

Major companies in the xerostomia therapeutics market are focusing on developing patient-friendly, non-invasive treatments such as oral sprays to meet the growing demand for convenient and effective solutions for managing dry mouth. Oral sprays allow for targeted application to the affected areas of the mouth, providing moisture and lubrication where needed. For example, in July 2023, K Pharmaceuticals, an India-based pharmaceutical company, launched Aquoral, a clinically proven oral spray designed to relieve dry mouth, also known as xerostomia. This condition, which can result from medications or diseases, causes discomfort, difficulties in chewing and swallowing, and oral health complications. Aquoral provides up to six hours of sustainable relief by forming a long-lasting protective barrier over the oral cavity, reducing moisture loss and enhancing comfort. Unlike traditional aqueous-based treatments that require frequent reapplication, Aquoral uses patented Oxidized Glycerol Triesters (OGT), a plant-derived lipid-based technology that offers superior protection.

In June 2022, Eagle Pharmaceuticals Inc., a US-based pharmaceutical company, completed the acquisition of Acacia Pharma Group plc for $104 million. This strategic move positions Eagle Pharmaceuticals as a significant player in the xerostomia therapeutics market, enhancing its product portfolio, market access, research and development capabilities, and potential for synergies and operational efficiencies. Acacia Pharma Group plc, headquartered in the UK, specializes in the development and commercialization of products aimed at addressing xerostomia and related conditions.

Major companies operating in the xerostomia therapeutics market are Bayer AG, 3M Company, GlaxoSmithKline plc, Colgate-Palmolive Company, Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Church & Dwight Co. Inc., Cipla Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Synedgen Inc., Sunstar Suisse S.A., Advanz Pharma Corp., Pharmascience Inc., Mission Pharmacal Company, Dentaid Ltd., Cyclacel Pharmaceuticals Inc., Parnell Pharmaceuticals Holdings Ltd., Teva Pharmaceutical Industries Ltd., Forward Science Holding Inc., ICPA Health Products Ltd., CCMed Ltd., Bio Cosmetics Laboratories S.L., Quest Products LLC, Acacia Pharma, Saliwell Limited, OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc.

North America was the largest region in the xerostomia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xerostomia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The xerostomia therapeutics market consists of revenues earned by entities by providing services such as medical consultations, pharmacological assistance, dental care, patient education, support services, and research and development, all geared towards treating and managing dry mouth. The market value includes the value of related goods sold by the service provider or included within the service offering. The xerostomia therapeutics market also includes sales of oral moisturizers, dental products such as fluoride treatments and saliva-stimulating mouthwashes, and oral lubricants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The xerostomia therapeutics market research report is one of a series of new reports that provides xerostomia therapeutics market statistics, including xerostomia therapeutics industry global market size, regional shares, competitors with a xerostomia therapeutics market share, detailed xerostomia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the xerostomia therapeutics industry. This xerostomia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xerostomia therapeutics encompass treatments and medications utilized to manage dry mouth, a condition characterized by reduced saliva production. These therapies aim to alleviate symptoms such as difficulty swallowing and tasting, as well as prevent dental issues.

The main types of xerostomia therapeutics include artificial saliva or saliva substitutes, and salivary stimulants. Artificial saliva or saliva substitutes are products specifically formulated to replicate the natural properties of saliva, providing lubrication, moisture, and protection to the oral tissues. They are distributed through various channels including hospital pharmacies, retail pharmacies, drug stores, mail order pharmacies, as well as hypermarkets and supermarkets, catering to both adult and pediatric end users.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.